Larimar Therapeutics, Inc. (NASDAQ:LRMR) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC grew its stake in shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) by 45.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 513,542 shares of the company's stock after acquiring an additional 159,700 shares during the quarter. Renaissance Technologies LLC owned about 0.80% of Larimar Therapeutics worth $1,987,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the stock. Barclays PLC grew its position in shares of Larimar Therapeutics by 321.2% during the 3rd quarter. Barclays PLC now owns 60,032 shares of the company's stock worth $393,000 after buying an additional 45,781 shares during the period. SG Americas Securities LLC lifted its stake in shares of Larimar Therapeutics by 35.1% during the 4th quarter. SG Americas Securities LLC now owns 19,391 shares of the company's stock valued at $75,000 after buying an additional 5,042 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Larimar Therapeutics by 21.9% in the third quarter. Franklin Resources Inc. now owns 19,723 shares of the company's stock worth $143,000 after acquiring an additional 3,549 shares during the period. Jane Street Group LLC increased its position in shares of Larimar Therapeutics by 80.1% during the third quarter. Jane Street Group LLC now owns 113,783 shares of the company's stock valued at $745,000 after buying an additional 50,622 shares during the period. Finally, JPMorgan Chase & Co. boosted its stake in Larimar Therapeutics by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 21,771 shares of the company's stock valued at $143,000 after buying an additional 3,425 shares during the period. Institutional investors own 91.92% of the company's stock.

Analysts Set New Price Targets

LRMR has been the topic of a number of analyst reports. Guggenheim reiterated a "buy" rating and issued a $26.00 price target on shares of Larimar Therapeutics in a research note on Tuesday, March 25th. Truist Financial began coverage on shares of Larimar Therapeutics in a research note on Wednesday, January 29th. They issued a "buy" rating and a $18.00 price target for the company. Robert W. Baird lowered their price objective on shares of Larimar Therapeutics from $13.00 to $10.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 25th. HC Wainwright lifted their target price on shares of Larimar Therapeutics from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, March 25th. Finally, Citigroup reissued a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, March 25th. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Buy" and a consensus target price of $19.63.

Larimar Therapeutics Price Performance

Shares of LRMR stock traded up $0.17 during trading hours on Thursday, hitting $2.82. The stock had a trading volume of 624,682 shares, compared to its average volume of 777,587. The stock's 50 day moving average is $2.36 and its 200 day moving average is $4.31. Larimar Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $11.20. The firm has a market capitalization of $180.43 million, a PE ratio of -2.45 and a beta of 0.91.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by ($0.16). As a group, equities analysts predict that Larimar Therapeutics, Inc. will post -1.15 earnings per share for the current year.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.